Harvard Bioscience — Third Quarter 2026 Earnings Summary

Harvard Bioscience reported third-quarter 2026 revenue of $22.2 million, representing an 8% year-over-year increase, while reaffirming full-year revenue growth guidance of 3% to 5%. The company posted a net loss of $2.6 million for the quarter and $9.0 million for the first nine months, a significant improvement from the $53.9 million loss in the prior year period driven by a goodwill impairment charge. Adjusted EBITDA for the quarter was $1.8 million, and the company expects fourth-quarter revenue to range between $23.7 million and $25.5 million with adjusted EBITDA between $3.8 million and $4.2 million.